**Chapter 6**

*Pathogenic Bacteria*

[41] Evers S, Courvalin P. Regulation of VanB-type vancomycin resistance gene expression by the VanS(B)-VanR(B) two-component regulatory system in *Enterococcus faecalis* V583. Journal of Bacteriology. 1996;**178**:1302-1309

isolation and identification of the pheromone-responsive plasmids pMG2200, encoding VanB-type

10.1128/AAC.00754-08

10.1017/S0950268812001574

journal.pone.0193926

10.1128/AAC.00714-11

CMR.00088-17

[50] Kohler P, Eshaghi A, Kim HC, Plevneshi A, Green K, Willey BM, et al. Toronto invasive bacterial diseases network (TIBDN). Prevalence of vancomycin-variable *Enterococcus faecium* (VVE) among *vanA*-positive sterile site isolates and patient factors associated with VVE bacteremia. PLoS ONE. 2018;**13**:e0193926. DOI: 10.1371/

[51] Lebreton F, Depardieu F, Bourdon N, Fines-Guyon M, Berger P, Camiade S, et al. D-Ala-d-Ser VanN-type transferable vancomycin resistance in *Enterococcus faecium*. Antimicrobial Agents and Chemotherapy. 2011;**55**:4606-4612. DOI:

[52] Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile genetic elements associated with antimicrobial resistance.

Clinical Microbiology Reviews. 2018;**31**:e00088-e00017. DOI: 10.1128/

[53] Patel R, Piper K, Cockerill FR 3rd, Steckelberg JM, Yousten AA. The biopesticide *Paenibacillus popilliae* has a vancomycin resistance gene cluster homologous to the enterococcal VanA vancomycin resistance gene cluster. Antimicrobial Agents and Chemotherapy. 2000;**44**:705-709

vancomycin resistance and a Bac41-type bacteriocin, and pMG2201, encoding erythromycin resistance and cytolysin (Hly/Bac). Antimicrobial Agents and Chemotherapy. 2009;**53**:735-747. DOI:

[49] Khan MA, Shorman M, Al-Tawfiq JA, Hays JP. New type F lineage-related Tn*1546* and a *vanA*/*vanB* type

vancomycin-resistant *Enterococcus faecium* isolated from patients in Dammam, Saudi Arabia during 2006-2007. Epidemiololgy and Infection. 2013;**141**:1109-1114. DOI:

[42] Coburn B, Low DE, Patel SN, Poutanen SM, Shahinas D, Eshaghi A, et al. Vancomycin-variable *Enterococcus* 

vancomycin resistance in a vancomycinsusceptible isolate. Journal of Clinical Microbiology. 2014;**52**:1766-1767. DOI:

[43] Arthur M, Molinas C, Depardieu F, Courvalin P. Characterization of Tn*1546*, a Tn*3*-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in *Enterococcus faecium* BM4147. Journal of Bacteriology. 1993;**175**:117-127

[44] Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC. Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrobial Agents and Chemotherapy. 1993;**37**:2311-2317

[45] Garnier F, Taourit S, Glaser P, Courvalin P, Galimand M. Characterization of transposon Tn*1549*, conferring VanBtype resistance in *Enterococcus* spp. Microbiology. 2000;**146**:1481-1489

[46] Perichon B, Courvalin P. VanA-type vancomycin-resistant *Staphylococcus aureus*. Antimicrobial Agents and Chemotherapy. 2009;**53**:4580-4587. DOI: 10.1128/AAC.00346-09

[47] Sarti M, Campanile F, Sabia C, Santagati M, Gargiulo R, Stefani S. Polyclonaldiffusion of Beta-lactamaseproducing *Enterococcus faecium*. Journal of Clinical Microbiology. 2012;**50**:169- 172. DOI: 10.1128/JCM.05640-11

[48] Zheng B, Tomita H, Inoue T, Ike Y. Isolation of VanB-type *Enterococcus faecalis* strains from nosocomial infections: First report of the

*faecium*: *In vivo* emergence of

10.1128/JCM.03579-13

**82**
